Core Viewpoint - The company has achieved a significant technological breakthrough with its serum-free iterative rabies vaccine, which is expected to fill a market gap as it is the first of its kind to be approved for sale globally [1][2] Group 1: Product Development and Approval - The company's subsidiary, Aimeirongyu (Ningbo) Biopharmaceutical Co., Ltd., has successfully passed the clinical trial site inspection and drug registration production site inspection for its serum-free iterative rabies vaccine [1] - The Phase III clinical study results indicate that the vaccine demonstrates good safety, immunogenicity, and durability, meeting all preset evaluation standards [1] - The company has obtained the necessary production license for the serum-free iterative rabies vaccine, positioning itself for a market launch [1] Group 2: Market Potential and Competitive Advantage - China is the largest rabies vaccine market globally, projected to reach 14.8 billion yuan by 2030, driven by product updates and increased vaccine adoption [2] - The new vaccine's lack of animal serum significantly enhances safety and reduces the likelihood of adverse reactions, making it a preferred choice for vaccination institutions [2] - As the second-largest supplier of rabies vaccines globally, the company aims to lead in the deep technological iteration and upgrade of rabies vaccines, with the capability for large-scale production once the product is approved [2]
艾美疫苗全球自主首研的无血清迭代狂犬疫苗顺利通过注册现场检查